In the phase 1 trials in healthy subjects, obicetrapib showed already near maximal CETP inhibition with daily doses of only 2.5 mg.43 The Phase 2 dose finding trial of obicetrapib, TULIP (TA-8995-03: Its Use in Patients with Mild Dyslipidaemia) was performed in 364 participants with dyslipidaemia receiving obicetrapib up to 10 mg once daily for 12 weeks.44 The 5 mg dose achieved reductions in LDL-C (measured with the gold standard beta quantification) and apoB of 45% and 34%, respectively, whereas HDL-C was increased with 157%. The gene discussed is CETP; the disease is inherited lipid metabolism disorder.